Celosia develops gene therapies that target the underlying mechanisms of neurodegenerative diseases such as ALS and frontotemporal dementia. Its lead candidate, CTX1000, is a first‑in‑class therapy designed to reduce toxic TDP‑43 protein accumulation, with IND submission underway and patient dosing planned for 2025. The company’s pipeline also includes programs for ALS, Alzheimer’s disease, and epilepsy syndromes.
Funding
$18.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Neurodegenerative diseases like ALS, Alzheimer’s, and frontotemporal dementia lack effective treatments, leaving patients with limited options and poor prognoses. Current therapeutic approaches often fail to address the underlying molecular mechanisms contributing to these debilitating conditions.
Solution
Celosia Therapeutics is developing gene therapies that modify the neuronal microenvironment to treat neurodegenerative diseases. Their approach leverages advances in gene therapy and a deeper understanding of the molecular pathways involved in these diseases. By targeting the root causes of neurodegeneration, Celosia aims to provide more effective and long-lasting therapeutic solutions for patients suffering from ALS, Alzheimer’s disease, frontotemporal dementia, and Dravet Syndrome.
Target Audience
The primary target audience includes patients suffering from neurodegenerative diseases such as ALS, Alzheimer’s, and frontotemporal dementia, as well as their families and caregivers.
Features
- Gene therapy-based approach to modify the neuronal microenvironment
- Focus on addressing the underlying molecular mechanisms of neurodegenerative diseases
- Development of treatments for ALS, Alzheimer’s disease, frontotemporal dementia, and Dravet Syndrome